Skip to main content
. 2024 Feb 14;2:101829. doi: 10.1016/j.gimo.2024.101829

Table 1.

Characteristics of MPV cohort and single-gene controls

Sample Characteristic MPVs
Single-PV Controls
Total Controls
N (%)
N (%) ATM
N (%)
BRCA1
N (%)
BRCA2
N (%)
CHEK2
N (%)
PALB2
N (%)
Total N 653 1367 (15.4) 2535 (28.5) 2668 (30) 1605 (18.1) 708 (8) 8883 (100)
Sex
 Female 544 (83.3) 1275 (93.3) 2407 (95.0) 2425 (90.9) 1475 (91.9) 676 (95.5) 8258 (93.0)
 Male 109 (16.7) 92 (6.7) 128 (5.0) 243 (9.1) 130 (8.1) 32 (4.5) 625 (7.0)
Race, ethnicity, and ancestry
 African American/Black 19 (2.9) 58 (4.2) 228 (9.0) 234 (8.8) 24 (1.5) 45 (6.4) 589 (6.6)
 Ashkenazi Jewish 59 (9.0) 74 (5.4) 185 (7.3) 146 (5.5) 67 (4.2) 21 (3.0) 493 (5.5)
 Asian 14 (2.1) 36 (2.6) 127 (5.0) 136 (5.1) 16 (1.0) 35 (4.9) 350 (3.9)
 Hispanic 25 (3.8) 63 (4.6) 223 (8.8) 180 (6.7) 45 (2.8) 46 (6.5) 557 (6.3)
 White 440 (67.4) 936 (68.5) 1433 (56.5) 1604 (60.1) 1299 (80.9) 475 (67.1) 5747 (64.7)
 Other/Unknown 96 (14.7) 200 (14.6) 339 (13.4) 368 (13.7) 154 (9.6) 86 (12.1) 1147 (12.9)
Number of primary cancer(s)
 0 117 (17.9) 271 (19.8) 430 (17.0) 465 (17.4) 316 (19.7) 107 (15.1) a
 1 345 (52.8) 762 (55.7) 1542 (60.8) 1621 (60.8) 895 (55.8) 448 (63.3) a
 ≥2 182 (27.9) 299 (21.9) 490 (19.3) 506 (19.0) 365 (22.7) 144 (20.3) a
 Unknown 9 (1.4) 35 (2.6) 73 (2.9) 76 (2.8) 29 (1.8) 9 (1.3) a
Median age at genetic testing (IQR) 53 (19) 52 (19) 49 (20) 53 (21) 53 (20) 53 (19) 52 (19)
Median age at first cancer diagnosis (IQR) 46 (16) 47 (17) 44 (16) 49 (18) 47 (15) 48 (16) a
Breast cancer among females
 Yes 321 (59.0) 832 (65.3) 1483 (61.6) 1529 (63.1) 1023 (69.4) 524 (77.5) a
 No 215 (39.5) 410 (32.2) 854 (35.5) 829 (34.2) 428 (29.0) 143 (21.2) a
 Unknown 8 (1.5) 33 (2.6) 70 (2.9) 67 (2.8) 24 (1.6) 9 (1.3) a
Median age at first breast cancer diagnosis (IQR) among females 47 (16) 46 (15) 41 (15) 46 (16) 47 (15) 48 (15) a

IQR, interquartile range; MPV, multiple PVs in one individual (adjective); MPVs, multiple PVs in one individual (plural noun); PV, pathogenic or likely pathogenic variant.

a

Not analyzed because of heterogeneity.